Stockreport

The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections

Paratek Pharmaceuticals, Inc.  (PRTK) 
Last paratek pharmaceuticals, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.paratekpharma.com
PDF BOSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and comm [Read more]